While several marine polar lipids (PL) have exhibited cardioprotective properties through
their effects on the platelet-activating factor (PAF) pathways, salmon PL have not been tested so
far. In this study, the antithrombotic activities of salmon PL were assessed in human platelets
and the structural characterisation of bioactive salmon PL was performed by GC-MS and LC-MS
analyses. PL from fillets of Irish organic farmed salmon (Salmo salar) were extracted and separated
into several lipid subclasses by thin-layer chromatography (TLC), while their fatty acid profile
was fully characterised by GC-MS. Salmon total lipids (TL), total neutral lipids (TNL), total polar
lipids (TPL), and each PL subclass obtained by TLC were further assessed for their in vitro effects
towards PAF-induced and thrombin-induced platelet aggregation in human platelets. Salmon PL
exhibited antithrombotic effects on human platelet aggregation, mostly through their strong inhibitory
effects against the PAF pathway with IC50 values comparable to other marine PL, but with lower
effects towards the thrombin pathway. PL fractions corresponding to phosphatidylcholine and
phosphatidylethanolamine derivatives exhibited the most potent anti-PAF effects, while LC-MS
analysis putatively elucidated their structure/function relationship. Several diacyl-PC/PE and
alkyl-acyl-PC/PE species containing mostly docosahexaenoic acid at their sn-2 glycerol-backbone
may be responsible for the bioactivity. The data presented suggests that salmon contains PL with
strong antithrombotic bioactivities.